A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Recruiting · NCT06382987 · Observational (researchers observe without assigning treatment) · Lead sponsor: Bristol-Myers Squibb
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Japanese adult participants aged 18 years old or older
- Physician-reported diagnosis of plaque psoriasis
- Newly initiating deucravacitinib or apremilast according to the label
- Participants who have signed informed consent
Exclusion criteria
- Participants currently participating in or planning to participate in an interventional clinical trial
- Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
- Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)
Where it is running
2 locations listed.
- Fukuoka University Hospital - Fukuoka, Japan
- Mebix. Inc. - Minato-ku, Tokyo, Japan